Procyon (PCYN) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Procyon Corporation  (PCYN)
 

Procyon Growth Comparisons

Select each growth Category to receive further Information





PCYN Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 17.51 % 5.71 % 4.73 % 4.79 %
Q / Q Revenue Growth (Q2 MRQ) 17.87 % 5.76 % 3.39 % 3.35 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 6.35 % -1.22 % 3.13 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 4.41 % 1.3 % 1.21 % 1.16 %
Revenue 5 Year Average Growth 3.53 % 15.58 % 11.69 % 9.77 %


PCYN's Growth Comparisons in IV. Quarter 2024




Facing 17.51% year on year sales decrease in the fourth quarter 2024, to $ 1 millions, Procyon reported smaller declines than the Major Pharmaceutical Preparations industry with 5.71%, and less than 4.73% growth in the Healthcare sector. Comparing the fourth quarter sales growth, both the Major Pharmaceutical Preparations industry and Procyon Corporation outperformed 4.79% overall market increase.

Top-line improved by 17.87% from the third quarter. Looking into annual sales rise of 3.53%, and S & P 500's average yearly sales growth is 9.77% over the five years, including only Businesses with the fourth quarter 2024 Results. Procyon grew less than the market.


Growth Rates of PCYN's Income in the fourth quarter 2024


PCYN Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - 85.04 % 78.68 % 16.35 %
Sequential Operating Income Change (Q2 MRQ) - 98.57 % 47.92 % 1.7 %
Y / Y Operating Income Growth (Q2 TTM) - -46.59 % -25.63 % 5.26 %
Sequential Operating Income Growth (Q2 TTM) - 20.72 % 17.09 % 3.01 %
Operating Income 5 Year Avg. Change - 2.08 % 0.04 % 17.16 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - 188.89 % 83 % 22.21 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - 604.38 % 66.74 % 11.67 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - -36.69 % -31.14 % 8.35 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - 26.52 % 29.17 % 5.68 %
Income from Cont. Ops. 5 Year Avg. Change - -0.36 % -5.93 % 17.27 %

PCYN Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) 1159.27 % 188.86 % 86.62 % 17.88 %
Q / Q Net Income Growth (Q2 MRQ) - 610.79 % 74.37 % 9.81 %
Y / Y Net Income Change (Q2 TTM) - 1.28 % -1.41 % 7.95 %
Sequential Net Income Change (Q2 TTM) - 14.79 % 18.97 % 4.68 %
Net Income 5 Year Avg. Growth - 16.73 % 7.4 % 16.77 %

PCYN's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - 475.14 % 83 % 22.21 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - 552.7 % 66.74 % 11.67 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 5.55 %
EPS from Cont. Ops. 5 Year Avg. Growth - -15.46 % -5.93 % 17.27 %



PCYN EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - 475.07 % 86.62 % 17.27 %
Q / Q EPS Net Growth (Q2 MRQ) - 558.63 % 74.37 % 9.81 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 233.05 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 5.58 %
EPS Net 5 Year Avg. Change - 16.73 % 7.4 % 16.77 %



Procyon reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 475.07%, while Healthcare sector increased by 86.62%, and overall market improved by 17.88%.

The bottom-line improved by 17.87% from the third quarter. Looking into annual income per share rise of 3.53%, and S & P 500's average yearly income per share growth is 16.77% over the five years, including only Businesses with the fourth quarter 2024 earnings reports. Procyon grew less than the market.

PCYN Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) -98.33 % -15.27 % -7.17 % 24.83 %
Sequential Free Cash Flow Change (Q2 MRQ) -95.45 % -14.79 % 46.46 % 242.56 %
Y / Y Free Cash Flow Change (Q2 TTM) - -6 % -0.98 % 26.54 %
Sequential Free Cash Flow Change (Q2 TTM) - -3.56 % -2.4 % 12.84 %
Free Cash Flow 5 Year Avg. Change -34.51 % 15.66 % 10.64 % 18.09 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) -99.21 % - - -
Sequential Net Cash Flow Change (Q2 MRQ) -98.23 % - - -
Y / Y Net Cash Flow Change (Q2 TTM) - - - -
Sequential Net Cash Flow Change (Q2 TTM) - 434.39 % - -
Net Cash Flow 5 Year Avg. Change - -4.78 % 0.82 % -29.23 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -38.8 % -2.73 % 2.08 % 17.39 %
Sequential Capital Expenditures Change (Q2 MRQ) 16771.66 % 3.09 % 3.31 % 5.39 %
Y / Y Capital Expenditures Change (Q2 TTM) -18.86 % 3.89 % 4.12 % 85.21 %
Sequential Capital Expenditures Change (Q2 TTM) -29.8 % 1.61 % 1.47 % 23.17 %
Capital Expenditures 5 Year Avg. Change - 10.7 % 8.91 % 10.5 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.